| Name |
Organisation |
Position |
| Andy Takle (Chair of the group) |
Cancer Research UK |
Director of Clinical and Translational Research |
| Hilary Calvert |
Newcastle University |
Chair of the Cancer Research UK New Agents Committee (NAC) |
| Bob Jackson |
Independent consultant |
Chair of the Cancer Research UK Discovery Committee (DC) |
| Simon Campbell |
Independent consultant |
Former senior vice-president for worldwide discovery and medicinal research at Pfizer |
| Herman Waldmann |
University of Oxford |
Head of the Sir William Dunn School of Pathology |
| Peter Machin |
Independent consultant |
Previously senior vice-president in discovery research and vice-president of chemistry and screening at GlaxoSmithKline; previously head of chemistry at Roche |
| Fiona Marshall |
Independent consultant |
Chief scientific officer of Heptares Therapeutics Ltd (a MRC Laboratory of Molecular Biology spin-off drug discovery company) |
| John Tite |
Independent consultant |
Chief executive office of Bicycle Therapeutics in Cambridge, UK |
| Chris Swain |
Independent consultant |
Founder of Cambridge MedChem Consulting; previously at Merck UK. |